Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe

Lancet. 2000 Apr 1;355(9210):1158-9.


We compared survival from HIV-1 seroconversion before and during the periods of highly-active antiretroviral therapy (HAART). Survival expectations were substantially better for HIV-1-infected individuals in 1997-98 (HAART period) compared with those in 1986-96 (pre-HAART period). Estimated survival 10 years from seroconversion was also substantially better in the later period.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Cohort Studies
  • Europe / epidemiology
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / mortality*
  • HIV Seropositivity / mortality
  • HIV-1*
  • Humans
  • Male
  • Middle Aged
  • Risk Assessment
  • Survival Rate
  • Time Factors


  • Anti-HIV Agents